









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on June 2024

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Methoxyflurane	RED			In gynaecological outpatient procedures
Morphine hydrochloride trihydrate	RED			Patient controlled analgesia bags
Uromune	RED			
3) New formulations & extensions to use				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil this month				
4) Products considered by NICE				
<u>TA963: Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency</u>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
<u>TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma</u>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
5) Appeals against earlier decisions by the APC				
Nil this month				
6) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines and pathways were presented to and approved at the June 2024 meeting of the APC:

- Psoriatic arthritis pathway (Humber Dermatology)
- Psoriatic pathway (Humber Dermatology)
- High output stoma guidance
- Sick day guidance for type 2 diabetes

The following Drug information leaflets were presented to and approved at the June 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the June 2024 meeting of the APC:

- SCF Template
- Riluzole SCF
- Verapamil SCF

Other documents presented to and approved at the June 2024 meeting of the APC:

- Nil this month